2003, 2009]. A reason for this discrepancy might derive from the treatment cultures of the countries of study origin, i.e. Germany and Switzerland where negative attitudes were found and the United

Kingdom with positive attitudes of psychiatrists towards LAIs in the treatment of FEPs [Heres et al. 2011; Jaeger and Rossler, 2010; Patel et al. 2003, 2009]. The UK traditionally has a more assertive community mental health system available [Burns et al. 2001]. Nevertheless the UK studies reported 69% [Patel et al. 2003] and 52% [Patel et al. 2009] of clinicians believed that www.selleckchem.com/products/Cisplatin.html patients were less likely to accept depot than oral medication. Inhibitors,research,lifescience,medical There are only few hints that depots are really perceived as more selleck products coercive by patients [Patel et al. 2010], while other results indicate that acceptation rates of LAIs in FEPs are rather high [Weiden et al. 2009]. In summary, several studies found a strong Inhibitors,research,lifescience,medical emphasis by psychiatrists on patients’ assumed objection to depot antipsychotics while data on the actual attitude on depot antipsychotics

Inhibitors,research,lifescience,medical of FEP is scarce. There might be two main reasons for this presumption on the part of clinicians. First, owing to the long-established association of depot treatment as a coercive, stigmatizing therapy [Patel et al. 2003, 2009, 2010; Walburn et al. 2001], clinicians would be more sensitive in their approach to patients experiencing psychosis and receiving antipsychotic treatment for the first time. Second, former treatment guidelines and expert opinions suggested oral SGA drugs as first-line treatment [Emsley, 2009; Lehman et al. 2004]. Furthermore, until

now a clear statement towards the role of depot antipsychotics Inhibitors,research,lifescience,medical in FEPs is still missing [Barnes et al. 2009; Barnes, 2011]. Inhibitors,research,lifescience,medical Taking into account that in recent years many studies have focused on the clinical effectiveness of depot medications in FEPs [Emsley et al. 2008; Kim et al. 2008; Weiden et al. 2009], the lack of evidence about patient’s attitude towards LAIs is particularly worrisome. So why do the majority of psychiatrists presume that patients would dislike depot treatment instead of asking them what way of administration they would choose? One reason might be found in the therapeutic relationship that still might Cilengitide be distinguished by traditionally paternalistic self-conceptions of psychiatrists. This might lead to recommendations by the psychiatrist on the best possible treatment according to his or her beliefs instead of providing full information about actual treatment options to the patient and making a treatment decision conjointly. Until now psychiatrist-stated noncompliance and a history of multiple relapses have been used as patients’ attributes that would qualify them for depot treatment. This long-standing stereotype was confirmed in a cluster analysis by Heres and colleagues [Heres et al. 2008].